These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11566012)

  • 1. Sitaxsentan (ICOS-Texas Biotechnology).
    Wu-Wong JR
    Curr Opin Investig Drugs; 2001 Apr; 2(4):531-6. PubMed ID: 11566012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
    Widlitz AC; Barst RJ; Horn EM
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitaxsentan sodium for pulmonary hypertension.
    MacIntyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
    Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
    Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J
    Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Barst RJ
    Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TBC 11251. IPI 1040.
    Drugs R D; 1999 Jul; 2(1):38-9. PubMed ID: 10610280
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
    Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA
    Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitaxsentan for treatment of pulmonary hypertension.
    Wittbrodt ET; Abubakar A
    Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitaxsentan in pulmonary arterial hypertension.
    Apostolopoulou SC; Rammos S
    Chest; 2003 May; 123(5):1772; author reply 1772-3. PubMed ID: 12740304
    [No Abstract]   [Full Text] [Related]  

  • 12. Sitaxsentan in the management of pulmonary arterial hypertension.
    Benedict NJ
    Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Langleben D; Hirsch AM; Shalit E; Lesenko L; Barst RJ
    Chest; 2004 Oct; 126(4):1377-81. PubMed ID: 15486408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will endothelin receptor antagonists have a role in heart failure?
    Spieker LE; Lüscher TF
    Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.